- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00275418
Beta Carotene From Natural Source for Patients With Non-Active Crohn's Disease
Double-Blind Randomized Prospective Trial of Treatment With Natural Beta Carotene Vs. Placebo for Patients With Crohn's Disease in Remission
Many inflammatory disorders in the body are linked to oxidative tissue damage. Anti-oxidants that are present in many natural food sources may provide protection from such damage.
Beta carotene is an anti-oxidant vitamin present in many fruits and vegetables. The algae Dunaliella is particularly rich in beta carotene.
In this prospective trial we want to investigate whether beta carotene from Dunaliella may prevent exacerbations of Crohn's disease.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Patients with documented Crohn's disease who are at least 2 months in remission (CDAI<150) will be randomized to receive 60 mg beta carotene/day vs. placebo for 1 year.
The study medication will be taken in addition to regular treatment for Crohn's disease.
The protocol includes 5 visits (months 0, 3, 6, 9, 12). Each visit lasts 30-60 minutes and includes a brief interview, standard questionnaires, physical examination, and blood tests.
Exacerbation of Crohn's disease is defined as CDAI>150. The study hypothesis is that less patients treated with beta carotene will suffer an exacerbation than patients treated with placebo.
Study Type
Enrollment
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Haifa, Israel, 31048
- Recruiting
- Bnai Zion Medical Center
-
Contact:
- Matthias Carlebach, MD
- Phone Number: + 972-4-8359426
- Email: matthias.carlebach@b-zion.org.il
-
Contact:
- Alexandra Lavy, MD
- Phone Number: + 972-4-8359736
- Email: lavya@netvision.net.il
-
Sub-Investigator:
- Matthias Carlebach, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- patients with documented Crohn's disease in remission (CDAI<150) for at least two months, age 17-75 years
Exclusion Criteria:
- active Crohn's disease (CDAI>150), partial bowel obstruction, impending surgery, pregnancy, serious other diseases
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
|---|
|
CDAI score measured 3-monthly during treatment
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Alexandra Lavy, MD, Technion, Haifa, Israel
Study record dates
Study Major Dates
Study Start
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Gastrointestinal Diseases
- Gastroenteritis
- Intestinal Diseases
- Inflammatory Bowel Diseases
- Crohn Disease
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Protective Agents
- Micronutrients
- Vitamins
- Antioxidants
- Provitamins
- Beta Carotene
- Carotenoids
Other Study ID Numbers
- Beta Carotene 01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.